About Us
About Us
Cibus Therapeutics is a clinical-stage biotechnology company based in Palo Alto, California, focused on developing next-generation therapies for gastrointestinal diseases. Our core expertise lies in creating targeted small-molecule treatments designed to disrupt the complex inflammatory pathways driving conditions like Pancreatitis and IBD.
Founded by a team of experienced scientists, clinicians, and industry leaders, we bring together deep expertise in translational research, drug development, inflammation biology,and clinical expertise. Our work is grounded in advanced molecular science, backed by rigorous preclinical data, and aimed at delivering safe and effective therapies that address significant unmet medical needs.
With a collaborative mindset, we partner with leading academic institutions, research organizations, and patient advocacy groups to accelerate innovation and bring transformative treatments closer to those who need them most. By integrating cutting-edge discovery platforms with strategic clinical development, Cibus Therapeutics is setting a new benchmark in GI health innovation.
Our Mission
We are dedicated to developing safe, effective, and innovative therapies for pancreatitis and inflammatory bowel disease (IBD). By targeting key inflammatory pathways, we aim to deliver treatments that improve patient outcomes and set new standards in GI care.
Who We Are
Cibus Therapeutics is a clinical-stage biotech company based in Palo Alto, California. Founded by scientists and clinicians, we focus on advancing CBT-101, a small-molecule therapy designed to treat GI diseases by modulating complex inflammatory signals.
Our Vision
We envision a future where GI diseases no longer compromise quality of life. Through cutting-edge science, strategic partnerships, and patient-focused development, we aim to bring transformative therapies to those living with chronic GI conditions.
Why It Matters
Chronic pancreatitis (CP) and inflammatory bowel disease (IBD), including ulcerative colitis, affect millions worldwide, causing severe pain, disability, and reduced quality of life. At Cibus Therapeutics, we are dedicated to alleviating this burden through the development of innovative therapies that target the complex inflammatory cascades underlying these diseases. With no effective treatments available for CP and current IBD therapies falling short, our mission is to deliver transformative solutions that provide lasting relief and improved patient outcomes. Through pioneering drug discovery, rigorous clinical research, and a patient-centric approach, we strive to redefine the standard of care, offering hope to millions impacted by these chronic conditions.
